Tender detail
Open-house rebate agreements for biologic medicines 2026-08 – Filgrastim
Summary
The participating health insurers are seeking rebate agreements with pharmaceutical companies for the active substance filgrastim through an open-house procedure. The agreements have uniform terms, do not grant exclusivity and may run for up to 24 months, from 1 May 2026 at the earliest until 30 April 2028 at the latest. Companies may join the procedure at any time during the contract period.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.